Research To Practice

・

頻道・共 10 個節目

科學

科學

每月更新
科學

科學

每週更新
科學

科學

每月更新兩次
科學

科學

每週更新
科學

科學

每週更新
科學

科學

隔月更新
科學

科學

每週更新

1月27日

Endocrine-Based Therapy for HR-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series

Dr Angela DeMichele from the Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Seth Wander from Massachusetts General Hospital in Boston discuss real-world cases and recent clinical data surrounding the management of HR-positive breast cancer. CME information and select publications here.

1月27日

・

2 小時 1 分鐘
1月8日

Antibody-Drug Conjugates for Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series

Dr Javier Cortés from the International Breast Cancer Center in Barcelona, Spain, Dr Rita Nanda from the University of Chicago, Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood discuss key clinical data with antibody-drug conjugates for metastatic breast cancer and their expert perspectives surrounding its clinical applications. CME information and select publications here.

1月8日

・

1 小時 30 分鐘
3 天前 · 影片

Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase Modulators

Featuring perspectives from Dr Natalie S Callander and Dr Paul G Richardson, including the following topics: Introduction: Clinical Trials We LOVE to Discuss (0:00) Mechanism of Action of Cereblon E3 Ligase Modulators (CELMoDs) (8:42) Available Efficacy Data with CELMoDs in the Management of Relapsed/Refractory Multiple Myeloma (MM) (15:59) Extramedullary Disease (19:23) Spectrum and Management of CELMoD-Associated Adverse Events (30:12) Ongoing Phase II and III Trials Evaluating CELMoDs for MM (34:53) CME information and select publications

3 天前 · 影片

・

58 分鐘
4 天前 · 影片

Metastatic Bladder Cancer — Rapid Case Review Issue 2

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics: Case: A man in his early 60s with urothelial bladder cancer (UBC) is found to have metastatic disease shortly after surgery (0:00) Case: A man in his late 70s experiences disease progression after first- and second-line treatment for metastatic disease (7:39) Case: A fit man in his early 70s presents with metastatic disease (15:22) CME information and select publications

4 天前 · 影片

・

29 分鐘
2025/11/14

ER-Positive Metastatic Breast Cancer — A Roundtable Discussion on the Current and Future Role of Oral SERDs

Prof Francois-Clement Bidard from the Institut Curie in Paris, France, Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, Dr Rebecca Shatsky from the University of California San Diego Moores Cancer Center and Dr Seth Wander from Massachusetts General Hospital in Boston discuss recent updates on available and emerging treatment strategies involving oral SERDs for ER-positive metastatic breast cancer. CME information and select publications here.

2025/11/14

・

2 小時 31 分鐘
2月9日

Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N Moore

Dr Kathleen N Moore from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on available and novel treatment strategies with antibody-drug conjugates for ovarian cancer. CME information and select publications here.

2月9日

・

55 分鐘
2月12日

Squamous Cell Carcinoma of the A**l Canal — An Interview with Dr Marwan Fakih

Dr Marwah Fakih from the City of Hope Comprehensive Cancer Center in Duarte, California, discusses current and potential therapeutic strategies for the treatment of squamous cell carcinoma of the a**l canal. CME information and select publications here.

2月12日

・

37 分鐘
$Relapsed/Refractory Diffuse Large B-Cell Lymphoma — A Roundtable Discussion on Current and Future Management Strategies$

2025/02/24 · 影片

Relapsed/Refractory Diffuse Large B-Cell Lymphoma — A Roundtable Discussion on Current and Future Management Strategies

Featuring slide presentations and related discussion from Prof Martin Hutchings, Dr Manali Kamdar, Dr Matthew Lunning and Prof Gilles Salles, including the following topics: Evolving Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (0:00) Case: A 61-year-old man with Stage IV non-GCB DLBCL receives R-CHOP but experiences disease progression 8 months later (30:39) Case: A 68-year-old man with double-hit DLBCL who experiences disease progression on chemotherapy and second-line CAR T-cell therapy receives glofitamab (39:22) Incorporation of Bispecific Antibody Therapy into DLBCL Management — Prof Hutchings (45:25) Case: A 42-year-old man with progressive DLBCL refractory to 2 lines of therapy receives glofitamab with a durable response (1:07:30) Case: An 81-year-old woman with multiregimen-refractory DLBCL experiences a prolonged response to epcoritamab (1:14:25) Case: A 69-year-old man with follicular lymphoma transformed to DLBCL and refractory to 3 lines of treatment receives glofitamab (1:21:48) Selection and Sequencing of Other Available Therapies for Relapsed/Refractory (R/R) DLBCL — Prof Salles (1:24:37) Case: An 82-year-old woman with follicular lymphoma transformed to DLBCL receives tafasitamab/lenalidomide (1:42:05) Case: A 69-year-old man with urinary bladder carcinoma and recurrent GCB DLBCL receives loncastuximab tesirine (1:46:26) Promising Investigational Approaches for Patients with R/R DLBCL — Dr Lunning (2:00:37) Case: An 80-year-old woman with multiregimen-refractory GCB DLBCL seeks treatment requiring minimal clinic visits and receives loncastuximab tesirine (2:15:59) Case: A 54-year-old man with primary refractory non-GCB DLBCL receives CAR T-cell therapy, and follow-up imaging on day 29 demonstrates a Deauville score of 4 (2:25:22) CME information and select publications

2025/02/24 · 影片

・

2 小時 33 分鐘
2月10日

Prostate Cancer — Microlearning Activity 2 with Dr Rana R McKay: ESMO Congress 2025 Review

Dr McKay discusses the selection of and efficacy data with androgen pathway-targeting agents for patients with prostate cancer and reviews recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here.

2月10日

・

18 分鐘
2025/12/23

Toxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient Cases

Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from The University of Chicago in Illinois engage in an evidence-based discussion around real-world cases involving common toxicities associated with antibody-drug conjugates in the management of breast cancer. CME information and select publications here.

2025/12/23

・

1 小時

CME education for oncology clinicians. Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.